Company intelligence / Profile preview

Eczacıbaşı-Monrol Nuclear Products Co.

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Monrol is known for its high-quality radiopharmaceuticals and theranostic products, with a particularly strong focus on Lutetium-177 for cancer treatments.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

ANMI (Belgium): Collaborative agreement for the distribution of innovative theranostic radiopharmaceuticals.Telix Pharmaceuticals: Supply agreement for Lutetium-177.FutureChem: Clinical supply partnership for Lutetium-177.

Beyond the preview

Go deeper on Eczacıbaşı-Monrol Nuclear Products Co..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eczacıbaşı-Monrol Nuclear Products Co..